Back to News & Events
Annual Applied Research And Development Awards Announced
June 15, 2017
Awards Support Innovative Research Collaborations Between Academic Faculty and Regional Bioscience Companies
The Center for Biotechnology at Stony Brook University has announced the recipients of the 2017-2018 Applied Research & Development (ARAD) awards. The ARAD Program is designed to help bridge the gap between the early-stage technology discovery and development capabilities of the academic community, and the later-stage commercial development interests of the bioscience industry.
The program currently provides matching funds on a competitive basis to support collaborations between Stony Brook University faculty and New York State corporate partners in all areas of medical biotechnology. The primary interest is in supporting development of technologies that will help companies hit commercially relevant milestones, and that have the potential to positively impact the New York State economy.
Projects supported this year include the furthered development of an ICU temporary pacemaker, a novel Lymphoma treatment, a novel synthetic peptide based therapeutic for Osteoporosis, further development of an fMRI Dynamic Phantom, development of novel vaccines, third generation taxoid based nanomedicine for chemoresistant cancer, development of a polymeric heart valve, a drug delivery technology for treatment of gastrointestinal diseases, and the development of skin brightening agents.
“The Center’s Applied Research and Development Program speaks to the core of what our organization does – collaborate with New York State companies to help them develop commercially promising technologies that will lead to strategic partnerships, investment, corporate revenues, and job creation” said Diane Fabel, Director of Operations for the Center for Biotechnology. “Our academic institutions are incredible resources for bioscience companies to tap into when it comes to technology development, and promoting interactions between the two helps fuel the overall bioscience ecosystem in the region.”
The ARAD Program is part of a suite of programs and services provided by the Center for Biotechnology (CFB) focused on accelerating the development of biomedical technologies in order to have a positive impact on human health and society. The CFB is also the lead administrative institution for the Long Island Bioscience Hub (LIBH) an NIH-designated Research Evaluation and Commercialization Hub (REACH) established with a National Institutes of Health grant in 2015.
2017-2018 Applied Research and Development Awards
“Synthetic Osteogenic Peptide for Treatment of Osteoporosis” Ajes Life Sciences & Dr. Srinivas Pentyala
“fMRI Dynamic Phantom for Improved Detection of Resting State Brain Networks” ALA Scientific Instruments & Dr. Helmut Strey
“Continued Development of ICU Temporary Pacemaker” Avery Biomedical Inc & Dr. Wei Lin
“Novel Pleiotropic Skin Brightening Agents” Biocogent, LLC & Dr. Sanford Simon
“In vivo Testing of Vaccine Candidates” Codagenix, Inc & Dr. Eckard Wimmer
“A Novel Polymeric Valve for Transcatheter Aortic Valve Replacement” Polynova Cardiovascular, Inc. & Dr. Danny Bluestein
“Imaging the Targeted Delivery of Biologic Agents to the Colon for Local Therapeutic Action” Symbiotic Health Inc. & Dr. Peter M. Smith-Jones
“Eradication of an Oncogenic Herpesvirus as a Novel Intervention for Lymphoma” Theragnostic Technologies, Inc. & Dr. Laurie T. Krug
“Novel Cancer Stem Cell Cytotoxic Agent: Nano-Formulation IND-Enabling Studies” TargaGenix Inc. & Dr. Galina Botchkina
Download a PDF of the press release here.
Related Stories
WP_Query Object
(
[query] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
)
[query_vars] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] =>
[tag] =>
[cat] =>
[tag_id] =>
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[paged] => 0
[meta_key] =>
[meta_value] =>
[preview] =>
[s] =>
[sentence] =>
[title] =>
[fields] =>
[menu_order] =>
[embed] =>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post__not_in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[search_columns] => Array
(
)
[ignore_sticky_posts] =>
[suppress_filters] =>
[cache_results] => 1
[update_post_term_cache] => 1
[update_menu_item_cache] =>
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] =>
[comments_per_page] => 50
[no_found_rows] =>
[order] =>
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
)
[relation] => AND
[table_aliases:protected] => Array
(
)
[queried_terms] => Array
(
)
[primary_table] => wp_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
)
[relation] =>
[meta_table] =>
[meta_id_column] =>
[primary_table] =>
[primary_id_column] =>
[table_aliases:protected] => Array
(
)
[clauses:protected] => Array
(
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] => SELECT SQL_CALC_FOUND_ROWS wp_posts.ID
FROM wp_posts
WHERE 1=1 AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
ORDER BY RAND()
LIMIT 0, 3
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 4439
[post_author] => 3
[post_date] => 2024-07-30 15:29:07
[post_date_gmt] => 2024-07-30 19:29:07
[post_content] =>
CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.
The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.
Read more about IAMBIC and their recent funding here.
[post_title] => CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant
[post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant
[to_ping] =>
[pinged] =>
[post_modified] => 2024-11-19 10:50:15
[post_modified_gmt] => 2024-11-19 15:50:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4439
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 2997
[post_author] => 4
[post_date] => 2018-07-02 19:00:11
[post_date_gmt] => 2018-07-02 19:00:11
[post_content] => Former Pfizer Senior Scientist and Scout Anton Xavier has joined the Center for Biotechnology in the role of Assistant Director of Technology and Business Development. Within this role at the Center, Anton will focus on the development and implementation of technology and business development strategies that will increase sponsored research, company formation, strategic alliances, and investment with external partners. Anton will also provide oversight to the Center’s Commercialization Associates offering technology / business development services and education to entrepreneurial faculty and emerging companies.
During his tenure at Pfizer, Anton had duties within the External Science and Innovation group (ES&I) focusing on sourcing, screening, and evaluating early through to late stage (inter)national biopharma ventures, entrepreneurial academic PI technology, private/public/local government funded life science initiatives, and funding vehicles which aligned with Pfizer’s R&D interest for investment and strategic partnerships. Additionally, Anton led efforts within Pfizer R&D from discovery through to late stage development of targeted therapeutics for oncology indications.
Prior to Pfizer, Anton’s experience was within a wider field of bioscience, including regenerative medicine, infectious disease, and cardiovascular biology where he developed multiple therapeutic, platform, and diagnostic innovations for military and industrial needs.
Anton is currently a mentor and adjunct faculty member for early stage life science ventures with E-Lab NYC, ABCT (Accelerator for Biosciences in Connecticut), NSF’s I-Corps program, the British Consulate NYC, Business France, and Cornell / Columbia University, where he provides critical industry based science, strategy, and business development input for bio-venture development.
Anton earned a Master’s degree in Business Administration (MBA) from Cornell University’s Johnson Graduate School of Management, a Master of Science (MSc) in Toxicology from Imperial College London and a Bachelor of Science in Biochemistry with Microbiology from Queen Mary University of London.
Anton can be reached at the Center for Biotechnology by emailing anton.xavier@stonybrook.edu
[post_title] => Anton Xavier Joins CFB in Technology and Business Development Role
[post_excerpt] => Former Pfizer Senior Scientist and Scout will focus on the development and implementation of technology and business development strategies.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => anton-xavier-joins-cfb-in-technology-and-business-development-role
[to_ping] =>
[pinged] =>
[post_modified] => 2018-07-02 19:00:40
[post_modified_gmt] => 2018-07-02 19:00:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=2997
[menu_order] => 120
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 2039
[post_author] => 3
[post_date] => 2016-03-24 18:53:40
[post_date_gmt] => 2016-03-24 18:53:40
[post_content] => News 12 Long Island Recently highlighted Katarzyna Sawicka, Founder and President of ImmunoMatrix, a Stony Brook start-up and CFB client developing a technology that can deliver medication directly through the skin, no needles necessary. View the segment here.
[post_title] => “No More Needles” – News 12 LI Features ImmunoMatrix
[post_excerpt] => News 12 Long Island Recently highlighted Katarzyna Sawicka, Founder and President of ImmunoMatrix, a Stony Brook start-up and CFB client developing a technology that can deliver medication directly through the skin, no needles necessary.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => no-more-needles-news-12-li-features-immunomatrix
[to_ping] =>
[pinged] =>
[post_modified] => 2016-03-29 20:30:02
[post_modified_gmt] => 2016-03-29 20:30:02
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=2039
[menu_order] => 187
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 2907
[post_author] => 1
[post_date] => 2018-01-03 15:36:20
[post_date_gmt] => 2018-01-03 15:36:20
[post_content] => Funding Opportunity Now Available for 2018 Summer Cohort of I-Corps at NIH
Did you know that the NIH and CDC offer entrepreneurship training program for small businesses?
I-Corps at NIH is an experience-based program designed specifically for small biotech businesses. Through this 8-week program, you will learn how to build a strong business model that could help bring your technology to patients.
The Funding Opportunity Announcement (FOA) for 2018 Summer Cohort of I-Corps at NIH is now available: PA-18-517. More information sessions will be available in early 2018 to help you better understand the program. In the meantime, please refer to the following resources to learn more about the program:
- FOA: PA-18-517
- Application due date: March 5, 2018, by 5 PM local time
- Cohort schedule: June - August 2018
- Program Information: I-Corps at NIH Program Page
- Recordings of previous info sessions: Webinar Materials page
If you have any questions about the program, please contact NCI SBIR (
ncisbir@mail.nih.gov).
[post_title] => Entrepreneurship Training Program from NIH & CDC: I-Corps
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => entrepreneurship-training-program-from-nih-cdc-i-corps
[to_ping] =>
[pinged] =>
[post_modified] => 2018-01-23 14:38:26
[post_modified_gmt] => 2018-01-23 14:38:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=2907
[menu_order] => 130
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 4
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 4439
[post_author] => 3
[post_date] => 2024-07-30 15:29:07
[post_date_gmt] => 2024-07-30 19:29:07
[post_content] =>
CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.
The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.
Read more about IAMBIC and their recent funding here.
[post_title] => CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant
[post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant
[to_ping] =>
[pinged] =>
[post_modified] => 2024-11-19 10:50:15
[post_modified_gmt] => 2024-11-19 15:50:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4439
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[comment_count] => 0
[current_comment] => -1
[found_posts] => 261
[max_num_pages] => 87
[max_num_comment_pages] => 0
[is_single] =>
[is_preview] =>
[is_page] =>
[is_archive] =>
[is_date] =>
[is_year] =>
[is_month] =>
[is_day] =>
[is_time] =>
[is_author] =>
[is_category] =>
[is_tag] =>
[is_tax] =>
[is_search] =>
[is_feed] =>
[is_comment_feed] =>
[is_trackback] =>
[is_home] => 1
[is_privacy_policy] =>
[is_404] =>
[is_embed] =>
[is_paged] =>
[is_admin] =>
[is_attachment] =>
[is_singular] =>
[is_robots] =>
[is_favicon] =>
[is_posts_page] =>
[is_post_type_archive] =>
[query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0
[query_vars_changed:WP_Query:private] =>
[thumbnails_cached] =>
[allow_query_attachment_by_filename:protected] =>
[stopwords:WP_Query:private] =>
[compat_fields:WP_Query:private] => Array
(
[0] => query_vars_hash
[1] => query_vars_changed
)
[compat_methods:WP_Query:private] => Array
(
[0] => init_query_flags
[1] => parse_tax_query
)
)
July 30, 2024
More Information
July 2, 2018
More Information
March 24, 2016
More Information
January 3, 2018
More Information